Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given their written agreement to participate in the trial
- People aged 18 or older
- People who have been diagnosed with, or are suspected to have, a type of kidney cancer called clear cell renal cell carcinoma
- People whose life expectancy is at least 6 months
Who may not be able to join:
- People whose kidney mass has been identified as a spread (metastasis) from a different cancer elsewhere in the body
- People who currently have another type of cancer that requires active treatment
- People who have received chemotherapy, radiotherapy, or immunotherapy within the past 4 weeks
- People whose kidneys are not filtering blood efficiently enough, based on a specific kidney function measurement called GFR (confirm with trial site)
- Women who are pregnant or breastfeeding, or women who plan to become pregnant within the next 6 months
- People who have a psychiatric condition that is not currently under control
- People who are in a vulnerable situation (for example, those in detention), or people who have a serious non-cancer illness such as an infectious disease, an autoimmune condition, or a metabolic disorder
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kan Gong, Peking University First Hospital
Phone: (86)-010-83572075
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The diagnostic efficacy of 68Ga-C1 PET/CT in the evaluation of clear cell renal cell carcinoma; The diagnostic efficacy of 68Ga-C1 PET/CT in the evaluation of malignant tumors
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.